Inspira Technologies (IINN) Appoints Dekel Stavi to its Board

July 26, 2021 11:05 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN), today announced the expansion of its North American presence with the appointment of Dr. Dekel Stavi, MD, Senior Intensive Care Clinician, for the company's Medical Advisory Board. The appointment of Dr. Stavi to the company's Medical Advisory Board forms a part of Inspira's strategic future expansion into the North American market.

Dr. Stavi has considerable experience in leadership and Extracorporeal Life Support programs, cardiology aspects of Intensive Care Unit ("ICU") patients and treating hemato-oncology patients in ICUs. Prior to joining the interdepartmental program of critical care at the University of Toronto, he served as a senior intensive care physician at a leading Israeli hospital - the Tel Aviv Sourasky Medical Center (Ichilov), where he initiated its institutional extracorporeal membrane oxygenation (ECMO) program. Dr. Stavi's notable publications include "Outcomes of prolonged mechanical ventilation in patients who underwent bedside percutaneous dilatation tracheostomy in intermediate care units - a single center study" and "Outcome and survival following tracheostomy in patients ≥ 85 years old."

Dagi Ben-Noon, Inspira's Co-Founder and CEO commented: "The company welcomes Dr. Stavi to its Medical Advisory Board. Dr. Stavi has valuable experience in intensive care medicine. We believe that Dr. Stavi can significantly contribute to our future efforts to introduce our innovative respiratory technology to the medical community in the North American market."

Dr. Dekel Stavi, stated: "Providing the best care to patients is my first priority as a critical care professional. Extracorporeal technologies such as those being developed by Inspira would be a welcome addition to the oxygenating arena as a support system. To be a part of potentially bringing innovative technology to market for patients with refractory hypoxemia is an exciting opportunity for me."

"Inspira's Medical Advisory Board provides the company's management with external expertise, insight, and guidance on business development and clinical strategy. A combination of unique skill sets and interaction with patients is shared by all Medical Advisory Board members. Thus, they have a crucial role to play in tailoring the product to potentially be used by patients" Mr. Ben-Noon added.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Board Changes, Corporate News

Related Entities